A home for LASIK comments
This article was originally published in The Gray Sheet
Executive Summary
FDA establishes a dedicated docket for public comments on post-market experience with LASIK laser vision correction surgery, the agency announces Sept. 12. After updating its LASIK Web site and strengthening post-market surveillance activities, FDA says it wants to better understand post-treatment quality-of-life issues. LASIK complications have taken a high-profile in recent months, and on May 19 yet another citizen petition was filed urging FDA to ban the devices (1"The Gray Sheet" March 24, 2008, p. 6). Comments may be submitted to FDA-2008-N-0488 through Sept. 14, 2009
You may also be interested in...
Regulatory News In Brief
FDA may post 'untitled' letters online: FDA is considering posting on its Web site "untitled" letters issued to manufacturers. "In an era of enhanced enforcement and greater transparency, that's being discussed," according to Larry Spears, deputy director of regulatory affairs in CDRH's Office of Compliance. His comments came during FDAnews' recent Fourth Annual FDA Inspections Summit in Bethesda, Md. Currently, the agency only posts redacted warning letters online. "Untitled letters don't really meet the threshold of a warning letter," Spears said. "That means they're not significant enough that we would take a follow-up action necessarily with what we see, but there are problems that need to be identified to the company because we've looked at the evidence and believe there are problems. So we want to identify those in an untitled letter.
Post-LASIK Vision Correction Quality-Of-Life Will Be Reviewed By FDA Panel
FDA's Ophthalmic Devices Advisory Panel will address quality-of-life issues following LASIK laser vision correction surgery on the second day of its upcoming April 24-25 meeting
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.